tbuckley/cabot-search huggingface dataset:
p38 inhibition provides anti–DNA virus immunity by regulation of USP21 phosphorylation and STING activation
Authors: Yunfei Chen, Lufan Wang, Jiali Jin, Yi Luan, Cong Chen, Yu Li, Hongshang Chu, Xinbo Wang, Guanghong Liao, Yue Yu, Hongqi Teng, Yanming Wang, Weijuan Pan, Lan Fang, Lujian Liao, Zhengfan Jiang, Xin Ge, Bin Li, Ping Wang
Journal: The Journal of Experimental Medicine (2017)

Stimulator of IFN genes (STING) is a central adaptor protein that mediates the innate immune responses to DNA virus infection. Although ubiquitination is essential for STING function, how the ubiquitination/deubiquitination system is regulated by virus infection to control STING activity remains unknown. In this study, we found that USP21 is an important deubiquitinating enzyme for STING and that it negatively regulates the DNA virus–induced production of type I interferons by hydrolyzing K27/63-linked polyubiquitin chain on STING. HSV-1 infection recruited USP21 to STING at late stage by p38-mediated phosphorylation of USP21 at Ser538. Inhibition of p38 MAPK enhanced the production of IFNs in response to virus infection and protected mice from lethal HSV-1 infection. Thus, our study reveals a critical role of p38-mediated USP21 phosphorylation in regulating STING-mediated antiviral functions and identifies p38-USP21 axis as an important pathway that DNA virus adopts to avoid innate immunity responses.
Health behaviors not significantly changed by direct‐to‐consumer genetic testing
Authors: Mary Kay Barton
Journal: CA A Cancer Journal for Clinicians (2017)

Key Points SNP‐based cancer risk estimates do not appear to affect health‐related behaviors positively or negatively. DTC genetic testing will continue to evolve and become more complicated, and the health care provider is obligated to educate patients and refer them to genetic counselors appropriately.
Roles of Osteoclasts in Leukemic Cells
Authors: Asumi Yokota, Shinya Kimura, Ruriko Tanaka, Rina Nagao, Kazuki Sakai, Hisayuki Yao, Miki Takeuchi, Makoto Kawatani, Hiroyuki Osada, Eishi Ashihara, Taira Maekawa
Journal: Blood (2008)
A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers
Authors: Sharon Seiko Hori, Amelie M. Lutz, Ramasamy Paulmurugan, Sanjiv Sam Gambhir
Journal: Cancer Research (2017)

Abstract An effective cancer blood biomarker screening strategy must distinguish aggressive from nonaggressive tumors at an early, intervenable time. However, for blood-based strategies to be useful, the quantity of biomarker shed into the blood and its relationship to tumor growth or progression must be validated. To study how blood biomarker levels correlate with early-stage viable tumor growth in a mouse model of human cancer, we monitored early tumor growth of engineered human ovarian cancer cells (A2780) implanted orthotopically into nude mice. Biomarker shedding was monitored by serial blood sampling, whereas tumor viability and volume were monitored by bioluminescence imaging and ultrasound imaging. From these metrics, we developed a mathematical model of cancer biomarker kinetics that accounts for biomarker shedding from tumor and healthy cells, biomarker entry into vasculature, biomarker elimination from plasma, and subject-specific tumor growth. We validated the model in a separate set of mice in which subject-specific tumor growth rates were accurately predicted. To illustrate clinical translation of this strategy, we allometrically scaled model parameters from mouse to human and used parameters for PSA shedding and prostate cancer. In this manner, we found that blood biomarker sampling data alone were capable of enabling the detection and discrimination of simulated aggressive (2-month tumor doubling time) and nonaggressive (18-month tumor doubling time) tumors as early as 7.2 months and 8.9 years before clinical imaging, respectively. Our model and screening strategy offers broad impact in their applicability to any solid cancer and associated biomarkers shed, thereby allowing a distinction between aggressive and nonaggressive tumors using blood biomarker sampling data alone. Cancer Res; 77(10); 2570–84. ©2017 AACR.
Reticulate Hyperpigmentation in a Man With Hypohidrosis and Sinopulmonary Infections
Authors: Kiran Motaparthi, Brian Hall
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
The N6-Adenine Methyltransferase METTL14 Plays an Oncogenic Role in Acute Myeloid Leukemia
Authors: Huilin Huang, Hengyou Weng, Xi Qin, Boxuan Simen Zhao, Lou Dore, Jennifer Strong, Rui Su, Kyle Ferchen, Chenying Li, Lei Dong, Xi Jiang, Chuan He, Jianjun Chen
Journal: Blood (2016)
The Direct Anti-Tumor Activity of Enzastaurin (LY317615.HCl) and Its Primary Metabolite (LY326020.HCl) Is Evident in Preclinical DLBCL Models Regardless of Molecular Subtype
Authors: Jeremy R Graff, Ann M McNulty, Chad Dumstorf, Bruce Konicek, Chad Hall, Stephen Parsons
Journal: Blood (2012)
Correlation between MRD and Chimerism Kinetics in CLL Patients after Myeloablative and Non-Myeloablative Allogeneic Hematopoïetic Stem Cell Transplantation.
Authors: Adriana Plesa, Quoc-Hung Le, Daniela Revesz, Xavier Thomas, Sophie Ducastelle, Franck E. Nicolini, Anne-Sophie Michallet, Isabelle Mollet, Valerie Dubois, Melisa Clark, Charles Dumontet, Nicole Raus, Mauricette Michallet
Journal: Blood (2007)
Abstract P6-17-01: Adjuvant treatment with zoledronic acid (ZOL) in stage II/III breast cancer. The AZURE trial (BIG 01/04) 10 year follow-up
Authors: R Coleman, M Collinson, R Bell, H Marshall, D Dodwell, M Keane, M Gil, W Gregory, D Cameron
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
Abstract P5-10-10: Predictors of breast density among Black and Hispanic women presenting for mammographic screening
Authors: BA Oppong, C Dash, Y Li, K Makambi, T Coleman, L Adams-Campbell
Journal: Cancer Research (2017)

Abstract Background: Increased breast density has been associated with elevated breast cancer risk and complicating mammographic interpretation. Although previous studies have investigated population variations in breast density, Black and Hispanic women are often underrepresented in these analyses. Moreover, it is unclear how breast density differs between these ethnicities. We report on the mammographic density distribution of Black and Hispanic women having breast cancer screening at the Capital Breast Care Center (CBCC) and analyze factors associated with high breast density. Methods: Retrospective data from electronic medical records at a population-based mammography screening center were abstracted. From 2010 to 2014, data from women undergoing their first breast cancer screening were reviewed. Patient demographics including race, age at screening, education and menopausal status were abstracted in addition to body mass index (BMI) and Breast Imaging-Reporting and Data System (BI-RADS) density category:1- “fatty”, 2- “scattered fibroglandular densities”, 3- “heterogeneously dense” and 4- “extremely dense”. Logistic regression was used to investigate factors associated with breast density. Results: Density categorization was recorded for 1747 women over the five-year period, with 855 (49%) Black and 892 (51%) Hispanic. Patient characteristics associated with high density (categories 3 and 4) were younger age, Hispanic ethnicity, nulliparity, premenopausal status, and BMI &amp;lt; 30 kg/m2. On multivariate logistic regression, Hispanic ethnicity, premenopausal status, and BMI &amp;lt; 30 kg/m2 were predictive of high mammographic density. Conclusion: In a sample of women presenting for mammographic screening at CBCC, Hispanic women were more likely to have higher breast density compared to Black women. After controlling for ethnicity, postmenopausal and obese women were less likely to have dense breasts. Additional investigation is needed to further study the impact of obesity on breast density in underserved minority women. Citation Format: Oppong BA, Dash C, Li Y, Makambi K, Coleman T, Adams-Campbell L. Predictors of breast density among Black and Hispanic women presenting for mammographic screening [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-10-10.
Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation — United States, 2013–2015
Authors: Kamil E. Barbour, Charles G. Helmick, Michael Boring, Teresa J. Brady
Journal: MMWR Morbidity and Mortality Weekly Report (2014)

In the United States, doctor-diagnosed arthritis is a common and disabling chronic condition. Arthritis can lead to severe joint pain and poor physical function, and it can negatively affect quality of life.CDC analyzed 2013-2015 data from the National Health Interview Survey, an annual, nationally representative, in-person interview survey of the health status and behaviors of the noninstitutionalized civilian U.S. adult population, to update previous prevalence estimates of arthritis and arthritis-attributable activity limitations.On average, during 2013-2015, 54.4 million (22.7%) adults had doctor-diagnosed arthritis, and 23.7 million (43.5% of those with arthritis) had arthritis-attributable activity limitations (an age-adjusted increase of approximately 20% in the proportion of adults with arthritis reporting activity limitations since 2002 [p-trend <0.001]). Among adults with heart disease, diabetes, and obesity, the prevalences of doctor-diagnosed arthritis were 49.3%, 47.1%, and 30.6%, respectively; the prevalences of arthritis-attributable activity limitations among adults with these conditions and arthritis were 54.5% (heart disease), 54.0% (diabetes), and 49.0% (obesity).The prevalence of arthritis is high, particularly among adults with comorbid conditions, such as heart disease, diabetes, and obesity. Furthermore, the prevalence of arthritis-attributable activity limitations is high and increasing over time. Approximately half of adults with arthritis and heart disease, arthritis and diabetes, or arthritis and obesity are limited by their arthritis. Greater use of evidence-based physical activity and self-management education interventions can reduce pain and improve function and quality of life for adults with arthritis and also for adults with other chronic conditions who might be limited by their arthritis.
Abstract P5-16-07: Non-anthracycline-containing docetaxel plus cyclophosphomide was inferior to docetaxel, anthracycline and cyclophosphomide in neoadjuvant treatment of triple negative or HER2 positive breast cancer: Long term follow-up result from NATT study
Authors: X Chen, G Ye, C Zhang, X Li, K Shen
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
Mutations in DCC cause isolated agenesis of the corpus callosum with incomplete penetrance
Authors: Ashley P L Marsh, Delphine Heron, Timothy J Edwards, Angélique Quartier, Charles Galea, Caroline Nava, Agnès Rastetter, Marie-Laure Moutard, Vicki Anderson, Pierre Bitoun, Jens Bunt, Anne Faudet, Catherine Garel, Greta Gillies, Ilan Gobius, Justine Guegan, Solveig Heide, Boris Keren, Fabien Lesne, Vesna Lukic, Simone A Mandelstam, George McGillivray, Alissandra McIlroy, Aurélie Méneret, Cyril Mignot, Laura R Morcom, Sylvie Odent, Annalisa Paolino, Kate Pope, Florence Riant, Gail A Robinson, Megan Spencer-Smith, Myriam Srour, Sarah E M Stephenson, Rick Tankard, Oriane Trouillard, Quentin Welniarz, Amanda Wood, Alexis Brice, Guy Rouleau, Tania Attié-Bitach, Martin B Delatycki, Jean-Louis Mandel, David J Amor, Emmanuel Roze, Amélie Piton, Melanie Bahlo, Thierry Billette de Villemeur, Elliott H Sherr, Richard J Leventer, Linda J Richards, Paul J Lockhart, Christel Depienne
Journal: Nature Genetics (2017)
Annals Consult Guys - Generation Gap: Stent to Stent
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2017)

Web Exclusives21 February 2017Annals Consult Guys - Generation Gap: Stent to StentFREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDSearch for more papers by this author and Howard H. Weitz, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0002 SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Annals Consult Guys brings a new perspective to the art and science of medicine with lively discussion and analysis of real-world cases and situations. They address medically relevant topics—whether they be poignant, thought-provoking, or just plain entertaining.For more videos from and information on Annals Consult Guys, visit go.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Richard FairleyNone30 April 2018 Calf clot I was interested in the recommendation for serial ultrasound once per week for two weeks yet the data did not show propagation for 1-3 months please comment Author, Article, and Disclosure InformationAffiliations: Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb, Janssen, Portola; Consultancies: Bristol-Myers Squibb, Janssen. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCorrection: Annals Consult Guys—Measuring Lipids: To Fast or Not to Fast 21 February 2017Volume 166, Issue 4Page: CG1KeywordsDisclosureResearch grantsResearch reporting guidelinesStent implantation ePublished: 21 February 2017 Issue Published: 21 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Circulating Malignant Clonal Cells in Peripheral Blood of Patients with Myelodysplastic Syndrome: Verification by Interphase Fluorescent in Situ Hybridization Study and Its Correlation with Bone Marrow Clonal Cells.
Authors: Miyoung Kim, Song-yee Kim, Cha Ja She, Sang Mee Hwang, Bo Ra Oh, Hee Won Moon, Sung-Soo Yoon, Dong Soon Lee
Journal: Blood (2009)
Abstract P1-09-12: Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit
Authors: F Puglisi, M Ceppi, F Cognetti, S De Placido, P Bruzzi, M De Laurentiis, G Bisagni, G Cavazzini, A Durando, A Turletti, E Valle, F Montemurro, S Barni, A Ardizzoni, T Gamucci, G Colantuoni, L Del Mastro
Journal: Cancer Research (2017)

Abstract Background In patients with node-positive early breast cancer (EBC), dose-dense adjuvant chemotherapy improves disease-free survival (DFS) compared with standard interval chemotherapy. The GIM2 trial supports the value of dose-dense chemotherapy and suggests that the benefit is present in patients with hormone receptor-negative or hormone receptor-positive tumours (Del Mastro et al. Lancet 2015). In order to individualize decision making, there is a need to examine the absolute treatment effects of dose dense chemotherapy according to patient and tumor characteristics. Patients and Methods The randomized phase III GIM2 trial enrolled 2091 patients. The primary endpoint was DFS. A continuous, composite measure of treatment benefit for each patient was determined from a Cox model incorporating potential predictive factors (age: 25-40/41-55/56-71; histological grade: 1+2/3; hormonal receptor status: positive/negative). Subpopulation treatment effect pattern plot methodology was used to reveal differential treatment effects on DFS according to composite index. The study focused on patients with HER2–negative disease (N=1287). Results On average, the magnitude of benefit with dose dense chemotherapy versus standard chemotherapy ranged widely across different subpopulations, as quantified by the composite measure of relevant variables. The highest benefit was observed in patients with high grade, hormone receptor-negative disease (hazard ratio for DFS 0.44, 95% CI 0.23-0.83). Of note, a relevant benefit was observed also in patients with high grade, hormone receptor-positive disease (hazard ratio for DFS 0.74, 95% CI 0.50-1.09). Conclusion The absolute improvement in DFS with dose dense adjuvant chemotherapy is substantial in some patients with node-positive HER2-negative breast cancer, particularly those regarded as having high index risk (hormone receptor-negative, high grade disease). Interestingly, a significant effect of dose dense chemotherapy was observed also in patients with hormone receptor-positive, high grade disease. Citation Format: Puglisi F, Ceppi M, Cognetti F, De Placido S, Bruzzi P, De Laurentiis M, Bisagni G, Cavazzini G, Durando A, Turletti A, Valle E, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Del Mastro L. Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-12.
Abstract P3-14-13: Total mastectomy and immediate breast reconstruction for breast cancer: A ten-year Canadian single institution experience
Authors: RJ Younan, M Al Khaldi, C Maalouf, M Guez, K Boulva, A robidoux, E Nassif, M Poljicak, J BouMerhi, C Bernier, E Patocskai
Journal: Cancer Research (2017)

Abstract Fear of high local recurrence rate associated with immediate breast reconstruction (IBR) following total mastectomy for breast cancer might be a contributing factor to the low rate of immediate reconstruction performed in Quebec. The aim of this study was to demonstrate the oncological safety of total mastectomy with immediate breast reconstruction. A retrospective chart review of all patients who underwent total mastectomy with immediate breast reconstruction at the University of Montreal Hospital Center between 2006 and 2015 was performed. 375 patients (420 cases) met the inclusion criteria. The mean age was 51.5 years (25-77). The median follow-up was 45.6 months (0.4-115.2). Clinical cancer staging was done according to the American Joint Committee on Cancer (AJCC) criteria. 349 cases (83.1%) were classified as Stage &amp;lt; cIIb and 71 cases (16.9%) as ≥ cIIb. 73 patients (19.5%) received neoadjuvant chemotherapy, 113 (30.1%) received adjuvant chemotherapy and 91 (21.7%) received postoperative radiotherapy. Only 4 patients (3.5%) had a significant delay in receiving adjuvant chemotherapy and 4 patients (4.4%) had a delay in initiation of radiotherapy. In total, there were 12 (2.6%) local recurrences and 29 (7.7%) distant recurrences. The results of this study demonstrate a low rate of local recurrence that is comparable to the current litterature. Total mastectomy in association with immediate breast reconstruction is therefore an oncologically safe approach for the treatment of breast cancer and should be more widely adopted by medical centers throughout Quebec. Citation Format: Younan RJ, Al Khaldi M, Maalouf C, Guez M, Boulva K, robidoux A, Nassif E, Poljicak M, BouMerhi J, Bernier C, Patocskai E. Total mastectomy and immediate breast reconstruction for breast cancer: A ten-year Canadian single institution experience [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-14-13.
Identification and Characterization of Three Novel Cytogenetically Cryptic EVI1 Rearrangements Identified in 27 AML Patients All Predicting An Unfavorable Outcome
Authors: Claudia Haferlach, Vera Grossmann, Melanie Zenger, Sonja Schindela, Alexander Kohlmann, Wolfgang Kern, Torsten Haferlach, Susanne Schnittger
Journal: Blood (2011)
FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Authors: Stephanie K. Watkins, Ziqiang Zhu, Elena Riboldi, Kim A. Shafer-Weaver, Katherine E.R. Stagliano, Martha M. Sklavos, Stefan Ambs, Hideo Yagita, Arthur A. Hurwitz
Journal: Journal of Clinical Investigation (2015)

At the request of the corresponding author, the JCI is retracting the paper "FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer" based on findings of data falsification and fabrication regarding Figures 1D and8A, likely data falsification regarding Figure 4A, likely falsification or fabrication regarding Figure 4B, and erroneous sample attribution in Table 1.
Epor Is Not Expressed or Functional in Primary Tumor Cells Isolated Directly From Human Primary and Metastatic Epithelial Tumors Including Breast, Non-Small Cell Lung, Colorectal, and Ovarian Tissues
Authors: Ian McCaffery, John M Rossi, Katherine L Paweletz, Yanyan Tudor, Steve Elliott, V Dan Fitzpatrick, C. Glenn Begley, Scott D Patterson
Journal: Blood (2011)